ACADIA Pharmaceuticals - ACAD Stock Forecast, Price & News

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last twelve months. There are currently 2 sell ratings, 7 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ACAD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACAD, but not buy additional shares or sell existing shares.
View ACAD analyst ratings or view top-rated stocks.

19 equities research analysts have issued 12 month target prices for ACADIA Pharmaceuticals' stock. Their ACAD share price forecasts range from $10.00 to $35.00. On average, they expect the company's stock price to reach $21.47 in the next year. This suggests a possible upside of 47.0% from the stock's current price.
View analysts price targets for ACAD or view top-rated stocks among Wall Street analysts.

ACADIA Pharmaceuticals' stock was trading at $23.34 at the beginning of 2022. Since then, ACAD stock has decreased by 37.4% and is now trading at $14.61.
View the best growth stocks for 2022 here.

ACADIA Pharmaceuticals saw a drop in short interest in November. As of November 15th, there was short interest totaling 9,040,000 shares, a drop of 13.4% from the October 31st total of 10,440,000 shares. Based on an average trading volume of 1,450,000 shares, the short-interest ratio is presently 6.2 days. Approximately 5.7% of the shares of the stock are sold short.
View ACADIA Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our ACAD earnings forecast.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) issued its quarterly earnings results on Wednesday, November, 2nd. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.18) by $0.01. The biopharmaceutical company earned $130.70 million during the quarter, compared to the consensus estimate of $139.04 million. ACADIA Pharmaceuticals had a negative net margin of 42.49% and a negative trailing twelve-month return on equity of 47.09%. ACADIA Pharmaceuticals's revenue for the quarter was down .7% on a year-over-year basis. During the same period in the previous year, the business posted ($0.09) earnings per share.

ACADIA Pharmaceuticals issued an update on its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $510.00 million-$520.00 million, compared to the consensus revenue estimate of $530.69 million.

8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL).

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

ACADIA Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.98%), BlackRock Inc. (6.16%), State Street Corp (4.19%), Price T Rowe Associates Inc. MD (3.02%), RTW Investments LP (2.27%) and First Trust Advisors LP (1.80%). Insiders that own company stock include Austin D Kim, Austin D Kim, Brendan Teehan, Bros Advisors Lp Baker, Elena Ridloff, James Kihara, James M Daly, Laura Brege, Mark C Schneyer, Michael J Yang, Srdjan R Stankovic, Srdjan R Stankovic and Stephen Davis.
View institutional ownership trends.

Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ACAD stock can currently be purchased for approximately $14.61.

ACADIA Pharmaceuticals (NASDAQ:ACAD) has a market capitalization of $2.37 billion and generates $484.14 million in revenue each year. The biopharmaceutical company earns $-167,870,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis.

The company employs 514 workers across the globe.

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The official website for the company is www.acadia-pharm.com. The biopharmaceutical company can be reached via phone at (858) 558-2871, via email at ir@acadia-pharm.com, or via fax at 858-558-2872.